Not provided
Not provided
Not provided
Not provided
Not provided
The FB4 trial has been terminated due to COVID-19.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Indiana University | OTHER |
| University of Alabama at Birmingham | OTHER |
| Framingham State University | OTHER |
| Baylor University |
Not provided
Not provided
Not provided
Not provided
This study will evaluate the effects of dietary carbohydrate and sugar consumption, independent of energy content, on body fatness and metabolism in a rigorous feeding study.
Many people with obesity can lose weight for a few months, but most have difficulty maintaining weight loss over the long term. Extensive research has shown that weight loss elicits biological adaptations - including a decline in energy expenditure and an increase in hunger - that promote weight regain. However, this observation leaves unanswered why average body weight has recently increased among populations that are mostly genetically stable. According to the Carbohydrate-Insulin Model, increased consumption of processed carbohydrates during the low-fat diet era of the last 40 years has raised the average body weight being defended by biological mechanisms on a population basis. Specifically, the investigators hypothesize that diets high in total carbohydrate (with or without added sugar) acting through increased insulin secretion, alter substrate partitioning toward storage in body fat, leading to increased hunger, slowing metabolism, and accumulation of body fat.
To test this hypothesis, the investigators plan a randomized-controlled feeding study involving 125 adults with obesity. During the run-in phase, participants will be given a hypocaloric very-low-carbohydrate (VLC) diet, with adjustment of energy intake to produce 15 ± 3% weight loss over 3 to 4 months on an outpatient basis. After weight stabilization, participants will be admitted to a residential center for 13 weeks. During the first 3 weeks, energy intake and expenditure will be closely monitored during weight-loss maintenance. Then, energy intake will be individually "locked" at levels equal to energy expenditure and participants will be administered one of three randomly-assigned test diets for 10 weeks. The test diets include VLC, High Carbohydrate-Low Sugar (HC-LS), and High Carbohydrate-High Sugar (HC-HS).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Very-Low Carbohydrate Diet | Experimental | Feeding study. Dietary composition (approximately): 75% fat |
|
| High-Carbohydrate Low-Sugar Diet | Experimental | Feeding study. Dietary composition (approximately): 25% fat 0% added sugars. |
|
| High-Carbohydrate High-Sugar Diet | Experimental | Feeding study. Dietary composition (approximately): 25% fat, 20% added sugars. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Feeding Study | Behavioral | Food provision throughout the study: 1) Run-In Phase (VLC diet, weight loss); 2) Residential Phase (3 different test diets, weight-loss maintenance). |
|
| Measure | Description | Time Frame |
|---|---|---|
| Body fat mass | Body composition assessed using a multi-component model | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Measure | Description | Time Frame |
|---|---|---|
| Lean body mass | Assessed using a multi-component model (difference between total body mass and fat mass) | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Body weight |
| Measure | Description | Time Frame |
|---|---|---|
| 1,5-anhydroglucitol (1,5-AG) | Possible future analyses of archived specimen | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Lipoprotein particle subfraction distribution |
Inclusion Criteria:
Exclusion Criteria:
Female-specific exclusion criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| David S Ludwig, MD, PhD | Boston Children's Hospital | Principal Investigator |
| David B Allison, PhD | Indiana University, Bloomington | Principal Investigator |
| Cara B Ebbeling, PhD | Boston Children's Hospital | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Warren Conference Center and Inn | Ashland | Massachusetts | 01721 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 24839118 | Background | Ludwig DS, Friedman MI. Increasing adiposity: consequence or cause of overeating? JAMA. 2014 Jun 4;311(21):2167-8. doi: 10.1001/jama.2014.4133. No abstract available. | |
| 22735432 | Background | Ebbeling CB, Swain JF, Feldman HA, Wong WW, Hachey DL, Garcia-Lago E, Ludwig DS. Effects of dietary composition on energy expenditure during weight-loss maintenance. JAMA. 2012 Jun 27;307(24):2627-34. doi: 10.1001/jama.2012.6607. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009765 | Obesity |
| D015431 | Weight Loss |
| ID | Term |
|---|---|
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| OTHER |
Not provided
Not provided
Not provided
Assessors conducting analyses of biospecimens, laboratory personnel, DXA technologists, and research nurses were blinded to random group assignment. They were not involved in the randomization process or any aspects of the intervention. The statistical team worked with masked labels for the diet arms.
|
Anthropometrics, assessed by calibrated scale, in kilograms (kg)
| Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Total energy expenditure (TEE) | Assessed using doubly labeled water methodology | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Resting energy expenditure (REE) | Assessed by indirect calorimetry using respiratory gas exchange methodology with a ventilated hood system | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Physical activity level, (moderate to vigorous) | Total minutes of moderate- to vigorous-intensity physical activity, assessed by accelerometry | Measurements made daily during 2 weeks at PWL, 2 weeks at END, and alternating non-assessment weeks of the residential phase and integrated into a unified outcome |
| Insulin sensitivity | Assessed by frequently-sampled oral glucose tolerance test [OGTT], calculated using plasma insulin and glucose values | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Insulin secretion | Assessed by frequently-sampled oral glucose tolerance test [OGTT], using plasma insulin at 30 minutes following the dose of dextrose | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Glycemic control | Hemoglobin A1c [HbA1c] | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Total cholesterol | Chronic disease risk factor | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| HDL-cholesterol | Chronic disease risk factor | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| LDL-cholesterol | Chronic disease risk factor | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Non-HDL cholesterol | Chronic disease risk factor | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Triglycerides | Chronic disease risk factor | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Plasminogen Activator Inhibitor-1 [PAI-1] | Indicator of coagulopathy | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| High-sensitivity C-reactive protein [hsCRP] | Indicator of chronic inflammation | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Uric acid | Indicator of risk for kidney stones, measured in blood | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Systolic blood pressure | Assessed by auscultation, mmHg | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Diastolic blood pressure | Assessed by auscultation, mmHg | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Thyroxine (T4) | Thyroid function | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Free T4 | Thyroid function | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Thyroid stimulating hormone [TSH] | Thyroid function | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Insulin-like growth factor-1 [IGF-1] | Growth hormone action | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Urine cortisol | Stress hormone, assessed using 24-hour urine collection | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Urine catecholamines | Stress hormone, assessed using 24-hour urine collection | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Leptin | Adipokine | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Total Adiponectin | Adipokine | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| High-molecular weight adiponectin | Adipokine | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Sleep | Total sleep time, sleep onset latency, wake after sleep onset, and sleep efficiency, assessed by accelerometry | Measurements made daily during 2 weeks at PWL, 2 weeks at END, and alternating non-assessment weeks of the residential phase and integrated into a unified outcome |
| Blood glucose | Assessed by continuous glucose monitoring (CGM) | Measurements made daily during residential phase (0 to 10 weeks) and integrated into a unified outcome |
| Ghrelin | Hormonal Control of Appetite | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Body Circumference | Assessed using a 3D body scan | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Post-prandial energy expenditure and respiratory quotient | Optional testing, assessed by indirect calorimetry using respiratory gas exchange | Single assessment in weeks 6 to 8 of residential study |
| Activation of insulin signaling pathways | Assessed by immunohistochemistry of phosphorylated insulin receptor and signaling proteins | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
Possible future analyses of archived specimen
| Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Fibrinogen | Possible future analyses of archived specimen | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Interleukin-6 (IL-6) | Possible future analyses of archived specimen | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Reverse triiodothyronine (rT3) | Possible future analyses of archived specimen | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Insulin-like growth factor-binding protein 3 (IGF-BP3) | Possible future analyses of archived specimen | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Luteinizing hormone (LH) | Possible future analyses of archived specimen | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Follicle stimulating hormone (FSH) | Possible future analyses of archived specimen | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Estradiol (E2) | Possible future analyses of archived specimen | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Testosterone (TST, total) | Possible future analyses of archived specimen | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Testosterone (TST, free) | Possible future analyses of archived specimen | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Metabolomics profile | Possible future analyses of archived specimen | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Biomarker of cholesterol synthesis | Possible future analyses of archived specimen | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Biomarker of cholesterol absorption | Possible future analyses of archived specimen | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| MicroRNA | Possible future analyses of archived specimen | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Gut microbiome | Possible future analyses of archived specimen | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Demographics (mediator/modifier) | Baseline covariate | Pre-weight loss baseline |
| Body composition (mediator/modifier) | Baseline covariate | Pre-weight loss baseline |
| Measure of glucose homeostasis (insulin-30) (mediator/modifier) | Baseline covariate | Pre-weight loss baseline |
| Measure of glucose homeostasis (insulin sensitivity) (mediator/modifier) | Baseline covariate | Pre-weight loss baseline |
| Measure of glucose homeostasis (glycemic control) (mediator/modifier) | Baseline covariate | Pre-weight loss baseline |
| Obesity related genetic risk (mediator/modifier) | Baseline covariate | Pre-weight loss baseline |
| Body composition (mediator/modifier) | Time varying covariate | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Measure of glucose homeostasis (insulin-30) (mediator/modifier) | Time varying covariate | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Measure of glucose homeostasis (insulin sensitivity) (mediator/modifier) | Time varying covariate | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Measure of glucose homeostasis (glycemic control) (mediator/modifier) | Time varying covariate | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Physical activity level (moderate to vigorous) (mediator/modifier) | Time varying covariate for total minutes of moderate to vigorous intensity physical activity, assessed by accelerometry. | Measurements made daily during 2 weeks at PWL, 2 weeks at END, and alternating non-assessment weeks of the residential phase and integrated into a unified outcome |
| Sex Hormone-Binding Globulin (SHBG) | Possible future analysis of archived specimen | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Urinary nitrogen | Archived for future analysis | End of residential (END, 10 weeks) |
| Glucagon-like peptide-1 (GLP-1) | Possible future analyses of archived samples | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Glucose-dependent insulinotropic polypeptide (GIP) | Possible future analyses of archived samples | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Glucagon | Possible future analyses of archived samples | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Oxytocin | Possible future analyses of archived samples | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| Oxyntomodulin | Possible future analyses of archived samples | Change from post-weight loss (PWL, 0 weeks) to end of residential study (END, 10 weeks) |
| 36796647 | Derived | Wong MC, Bennett JP, Leong LT, Tian IY, Liu YE, Kelly NN, McCarthy C, Wong JMW, Ebbeling CB, Ludwig DS, Irving BA, Scott MC, Stampley J, Davis B, Johannsen N, Matthews R, Vincellette C, Garber AK, Maskarinec G, Weiss E, Rood J, Varanoske AN, Pasiakos SM, Heymsfield SB, Shepherd JA. Monitoring body composition change for intervention studies with advancing 3D optical imaging technology in comparison to dual-energy X-ray absorptiometry. Am J Clin Nutr. 2023 Apr;117(4):802-813. doi: 10.1016/j.ajcnut.2023.02.006. Epub 2023 Feb 14. |
| 35108378 | Derived | Jansen LT, Yang N, Wong JMW, Mehta T, Allison DB, Ludwig DS, Ebbeling CB. Prolonged Glycemic Adaptation Following Transition From a Low- to High-Carbohydrate Diet: A Randomized Controlled Feeding Trial. Diabetes Care. 2022 Mar 1;45(3):576-584. doi: 10.2337/dc21-1970. |
| 34587231 | Derived | Wong JMW, Yu S, Ma C, Mehta T, Dickinson SL, Allison DB, Heymsfield SB, Ebbeling CB, Ludwig DS. Stimulated Insulin Secretion Predicts Changes in Body Composition Following Weight Loss in Adults with High BMI. J Nutr. 2022 Mar 3;152(3):655-662. doi: 10.1093/jn/nxab315. |
| D001835 |
| Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D001836 | Body Weight Changes |